|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-5.20/9.29
|
企業價值
63.29M
|
資產負債 |
每股賬面淨值
-1.80
|
現金流量 |
現金流量率
--
|
損益表 |
收益
63.91M
|
每股收益
12.39
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/15 10:14 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO(R) (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC. |